Ultra-high purity assurance：HPLC purity ≥99.5%, with structure confirmed by multiple methods including 1H NMR, 13C NMR, and HRMS (high-resolution mass spectrometry), meeting the stringent requirements of global regulatory agencies such as FDA and EMA for impurity reference standards.

Extreme condition stability：Stable for 36 months when stored at -20°C in the dark, and with a degradation rate <1% after heating at 60°C for 72 hours in solution (e.g., acetonitrile), suitable for long-term storage and high-temperature accelerated testing.

Precise process traceability：As a characteristic by-product of aryl halogenation reactions in aprocitentan synthesis, it specifically tracks the risk of polyhalogenated impurities caused by excessive brominated/chlorinated reagents, assisting in identifying process parameters.

Full lifecycle pharmaceutical quality control：Used for LC-MS/MS detection of this impurity in aprocitentan APIs, formulations, and stability samples, controlling its content ≤0.05% in accordance with ICH Q3B standards to ensure compliance with genotoxic impurity (GTIs) control requirements.

Complex process optimization：In polyhalogenation reactions of pyrimidine rings, monitoring impurity content (e.g., reducing impurity from 1.2% to 0.1% when the molar ratio of bromobenzene to chloropyrimidine is adjusted from 1:1.5 to 1:1.1) optimizes the ratio and feeding order of arylating reagents to reduce by-product formation.

Analytical method validation：Serves as a reference material for developing specific detection methods, such as sensitivity verification of ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS), with a limit of quantitation (LOQ) as low as 0.01μg/mL for trace impurity detection.

Toxicological risk assessment：Provides high-purity samples for GLP laboratories to support in vitro gene mutation tests (e.g., Ames test) and in vivo micronucleus tests, facilitating the establishment of safe exposure limits for impurities.

Cutting-edge detection technology：UPLC-MS/MS is employed using a C18 ultra-hydrophobic column (1.7μm, 2.1×100mm) with 0.1% formic acid aqueous solution-acetonitrile (gradient elution) as the mobile phase, combined with multiple reaction monitoring (MRM) mode, achieving a detection limit (LOD) as low as 0.005ppm for precise quantification of nanogram-level impurities.

Formation mechanism analysis：Studies show that impurity formation is positively correlated with the feeding rate of aryl bromides and reaction temperature. When the bromobenzene dropping rate exceeds 5mL/min or the reaction temperature exceeds 80°C, impurity formation increases by more than 3 times; slow dropping at low temperature (≤25°C) and introducing catalytic copper powder (0.5mol%) can reduce impurity formation by over 90%.

Safety evaluation progress：A 13-week subchronic toxicity test in rats showed no obvious toxic target organs at doses ≤20mg/kg, but an in vitro comet assay revealed a 1.8-fold increase in DNA damage index at high concentrations (≥50μg/mL), suggesting that the limit should be set at ≤0.03% based on toxicological data to ensure drug safety.